Report
EUR 93.10
For Business Accounts Only
Despite having been listed just around a year ago, the stock has already seen two placements, both in Jan 2021, just after the lock-up expiry. Both the past deals did well. However, the stock was trading a whole lot lower at that time.
In this note, we will run the deal through our ECM framework and talk about the deal dynamics.
We covered the IPO across a series of note, links to which are below:
Hygeia Healthcare (海吉亚) Pre-IPO: The making of Jinxin in the oncology segment
Hygeia Healthcare (海吉亚) Pre-IPO: PHIP Updates and Thoughts on Valuation
Hygeia Healthcare (海吉亚) IPO: Hot Deal but Expect Tiny Allocation
Hygeia Healthcare (海吉亚) IPO Trading: Upside Might Take Time to Crystalize
Hygeia Healthcare placement
Warburg Pincus aims to raise around US$216m via selling 3.2% of Hygeia Healthcare. This won’t be the first selldown by Warburg.Despite having been listed just around a year ago, the stock has already seen two placements, both in Jan 2021, just after the lock-up expiry. Both the past deals did well. However, the stock was trading a whole lot lower at that time.
In this note, we will run the deal through our ECM framework and talk about the deal dynamics.
We covered the IPO across a series of note, links to which are below:
Hygeia Healthcare (海吉亚) Pre-IPO: The making of Jinxin in the oncology segment
Hygeia Healthcare (海吉亚) Pre-IPO: PHIP Updates and Thoughts on Valuation
Hygeia Healthcare (海吉亚) IPO: Hot Deal but Expect Tiny Allocation
Hygeia Healthcare (海吉亚) IPO Trading: Upside Might Take Time to Crystalize
Underlying
Hygeia Healthcare Holdings Co Ltd
Provider
Aequitas Research
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Sumeet Singh
Other Reports on these Companies
Other Reports from Aequitas Research
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.